J&J's (JNJ) Experimental TB Drug Receives Unanimous FDA Panel Backing

Article Related Articles (1) Stock Quotes (1) Comments (0)

Johnson & Johnson (NYSE: JNJ) got some good news late Wednesday after an FDA panel said it would back its experimental tuberculosis drug, bedaquiline.

The drug targets adenosine triphosphate synthase, which is an enzyme that TB needs to generate energy.

The FDA panel voted 10 to 0 on the matter, commenting that clinical trial data supported efficacy of bedaquiline in adults, taken in combination with standard treatments.

Johnson & Johnson plans to commence a phase 3 in the fourth quarter. Shares are flat in late trading.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Peregrine Pharma (PPHM), FDA Reach Agreement Over Bavituximab Phase III Design
• Alnylam (ALNY) Updates on Preclinical Data for RNAi Program Targeting ALAS-1
• Mylan (MYL) Launches Generic Tricor Tabs (ABBV)

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?